Literature DB >> 16977460

Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.

Paula P Lajolo1, Auro del Giglio.   

Abstract

BACKGROUND: 5HT-3 antagonists and corticosteroids control less than 50% of delayed chemotherapy induced nausea and vomiting (CINV) episodes.
MATERIALS AND METHODS: Two pilot phase II studies were conducted at our institution in which all patients received ondansetron 16 mg and dexamethasone 20 mg before highly and moderately emetogenic chemotherapy on day 1. Patients on study 1 received metoclopramide 10 mg PO q8 h, granisetron 0.5 mg PO QD and dexamethasone 8 mg QD on days 2 and 3, whereas only metoclopramide was continued on the same schedule on day 4. On study 2, patients received the same medications, but no drugs were given on day 2, and the same treatment schedule was given to them but from days 3 to 5 instead. Patients were interviewed on days 1 and 6.
RESULTS: Twenty-one patients participated on each study. There were no significant clinical differences between these two studied populations. Complete CINV control occurred from days 2 to 5 in 23.1% (95% CI: 8 to 47%) on study 1 vs 61.9% (95% CI: 38 to 81%) of the patients on study 2. By logistic regression, complete CINV control was correlated significantly with antiemetic treatment group (p=0.011) even when we considered only patients who achieved complete CINV control during the first 24 h (p=0.031).
CONCLUSIONS: Skipping day 2 antiemetic medications does not seem to worsen delayed CINV control and may even improve it, perhaps by avoiding tachyphylaxis to these medications. A randomized controlled study is in progress to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16977460     DOI: 10.1007/s00520-006-0134-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

1.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

Authors:  R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

2.  Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.

Authors: 
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

3.  Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study.

Authors:  Janise Moreno; Marina Sahade; Auro del Giglio
Journal:  Support Care Cancer       Date:  2005-04-19       Impact factor: 3.603

4.  Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.

Authors:  Richard J Gralla; Ronald de Wit; Jorn Herrstedt; Alexandra D Carides; Juliana Ianus; Julie Guoguang-Ma; Judith K Evans; Kevin J Horgan
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

Review 5.  Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

Authors:  Mark G Kris; Paul J Hesketh; Jorn Herrstedt; Cynthia Rittenberg; Lawrence H Einhorn; Steven Grunberg; Jim Koeller; Ian Olver; Sussanne Borjeson; Enzo Ballatori
Journal:  Support Care Cancer       Date:  2004-11-23       Impact factor: 3.603

6.  Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.

Authors:  Georgia M Decker; Elaine S DeMeyer; Deborah L Kisko
Journal:  J Support Oncol       Date:  2006-01

7.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Authors:  Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

8.  Actions of serotonin antagonists on cholera-toxin-induced intestinal fluid secretion.

Authors:  A Sjöqvist; J Cassuto; M Jodal; O Lundgren
Journal:  Acta Physiol Scand       Date:  1992-07

9.  Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients.

Authors:  S M Mullin; D M Fletcher; L S Tyler
Journal:  Am J Health Syst Pharm       Date:  1998-09-15       Impact factor: 2.637

10.  Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.

Authors:  S M Fox; L H Einhorn; E Cox; N Powell; A Abdy
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544

  10 in total
  1 in total

1.  Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study.

Authors:  Stephen B Freedman; Elizabeth C Powell; Alejandro A Nava-Ocampo; Yaron Finkelstein
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.